Wenhui Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wenhui Wang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Guiyan Liu
Department of General Surgery, The Affiliated Jianhu Hospital of Xinglin College, Nantong University, Jianhu People’s Hospital, 224700 Yancheng, Jiangsu, China
1 shared publication - Jie Mei
The First Clinical Medicine College, Nanjing Medical University, Nanjing, China
1 shared publication - Kai Yang
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, P. R. China
1 shared publication - Lili Wang
Department of General Surgery, The Affiliated Jianhu Hospital of Xinglin College, Nantong University, Jianhu People’s Hospital, 224700 Yancheng, Jiangsu, China
1 shared publication - Xinkang Zhang
Department of Oncology, The First Clinical Medicine College, Nanjing Medical University, 210029 Nanjing, Jiangsu, China
1 shared publication - Yinxin Zhang
Department of General Surgery, The Affiliated Jianhu Hospital of Xinglin College, Nantong University, Jianhu People’s Hospital, 224700 Yancheng, Jiangsu, China
1 shared publication
Latest Publications
- Open Access
- 22 December 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (12) , 45052
Collagen and Its Roles in the Tumor Immune Microenvironment: Structure, Function, and Therapeutic Potential
Collagen, the primary structural protein of the extracellular matrix, shows marked structure–function duality in the tumor immune microenvironment (TIME). Biomechanical and biophysical alterations—matrix stiffening, viscoelastic energy dissipation, fiber alignment and tumor-associated collagen signatures, reduced pore size, and solid stress—create migration tracks, sequester signaling cues that regulate proliferation and metabolism, and from dense barriers that impede immune infiltration. These changes are sensed and transduced via mechanosensing and mechanotransduction pathways, thereby reinforcing malignant behavior and immune exclusion. Given its dynamic, spatiotemporally regulated roles, collagen is a promising therapeutic target to overcome immunotherapy resistance. This review examines the structural features, biological functions, and regulatory pathways of collagen within the TIME. Based on these insights, several clinical strategies were highlighted: targeting cancerassociated fibroblasts and profibrotic signaling to reduce fibrosis; remodeling the matrix enzymatically or physically; and inhibiting collagen receptor signaling. These approaches are often combined with immune checkpoint inhibition. Future directions will emphasize biomarker-guided stratification of collagen status; combining therapies informed by mechanobiology; and using scalable, noninvasive monitoring to optimize immunotherapy outcomes.
- 22 December 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (12) , 45052
Open AccessCollagen and Its Roles in the Tumor Immune Microenvironment: Structure, Function, and Therapeutic Potential
Collagen, the primary structural protein of the extracellular matrix, shows marked structure–function duality in the tumor immune microenvironment (TIME). Biomechanical and biophysical alterations—matrix stiffening, viscoelastic energy dissipation, fiber alignment and tumor-associated collagen signatures, reduced pore size, and solid stress—create migration tracks, sequester signaling cues that regulate proliferation and metabolism, and from dense barriers that impede immune infiltration. These changes are sensed and transduced via mechanosensing and mechanotransduction pathways, thereby reinforcing malignant behavior and immune exclusion. Given its dynamic, spatiotemporally regulated roles, collagen is a promising therapeutic target to overcome immunotherapy resistance. This review examines the structural features, biological functions, and regulatory pathways of collagen within the TIME. Based on these insights, several clinical strategies were highlighted: targeting cancerassociated fibroblasts and profibrotic signaling to reduce fibrosis; remodeling the matrix enzymatically or physically; and inhibiting collagen receptor signaling. These approaches are often combined with immune checkpoint inhibition. Future directions will emphasize biomarker-guided stratification of collagen status; combining therapies informed by mechanobiology; and using scalable, noninvasive monitoring to optimize immunotherapy outcomes.